Serputinib/serpatinib is a drug developed and produced by which pharmaceutical company

Selpercatinib, trade name: Retevmo, is a RET gene-targeted drug Mutated oral tyrosine kinase inhibitors are mainly used to treat RETfusion-positive non-small cell lung cancer (NSCLC) and thyroid cancer. The drug was originally developed by Loxo Oncology, an American biotechnology company that focuses on developing precision cancer therapies that target specific genetic mutations. In 2019, Eli Lilly (Eli Lilly) acquired Loxo Oncology for approximately 8 billion billion, thereby obtaining the global development and commercialization rights of serpatinib.

In May 2020, the U.S. Food and Drug Administration (FDA) approved serpatinib for the treatment of breast cancer RETgene fusion for patients with advanced NSCLC and thyroid cancer, becoming the first targeted drug approved for RET driven cancer. Since then, serpatinib has been approved in multiple countries and regions, expanding its indications to include the treatment of patients with RET fusion-positive solid tumors.

In the Chinese market, serpatinib is developed and commercialized by Eli Lilly and Company in collaboration with Innovent Biologics (Innovent Biologics). In October 2022October , the China National Medical Products Administration (NMPA) approved serpatinib for the treatment of patients with RET fusion-positive NSCLC and thyroid cancer. According to the cooperation agreement between the two parties, Innovent Biologics is responsible for the import, pricing, marketing and sales of serpatinib in mainland China.

In addition, generic versions of serpatinib are also available in some countries. For example, BigBear Pharmaceutical in Laos produces a generic version of serpatinib called SEPADX with a specification40mgcapsules, used to treat RETfusion-positive NSCLC and thyroid cancer patients. The generic drug provides patients with a more economical treatment option.

Reference materials:https://en.wikipedia.org/wiki/Selpercatinib